Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Imitrex, zembrace symtouch, Imitrex statdose
Synonyms :
sumavel
Class :
Antimigraine agents/ Serotonin 5-HT-receptor agonists
Brand Name :
Imitrex, zembrace symtouch, Imitrex statdose
Synonyms :
sumavel
Class :
Antimigraine agents/ Serotonin 5-HT-receptor agonists
Dosage Forms & Strengths
Tablets
25mg
50mg
100mg
Nasal spray
20mg
Injectable solution
4mg/0.5mL
6mg/0.5mL
Tablet:
25mg,50mg, and 100mg taken orally
Do not exceed 100mg/dose
Maximum dose-200mg
Injection
6mg/0.5ml subcutaneous
Do not exceed 12mg subcutaneously every 24 hours
6
mg
Solution
Subcutaneous (SC)
as needed
Do not exceed 12mg subcutaneously every 24 hours
The dose should be selected cautiously in older patients
For patients undergoing initial therapy with subcutaneous injections
If migraine reoccurs after the first dose of SC injection, 100mg tablets orally once a day can be given as an additional dose, with at least a gap of 2 hours between the tablet doses
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the vasoconstricting effect of ergot Derivatives
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may enhance the serotonergic effect of monoamine oxidase inhibitors
may have an increasingly adverse effect when combined with sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
may have an increasingly adverse effect when combined with sumatriptan
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increased serotonergic effect when combined with monoamine oxidase inhibitors
may have an increasingly adverse effect when combined with sumatriptan
serotonin 5-HT1D receptor agonists increase the serotonergic effect of MAO inhibitors
may have an increased serotonergic effect when combined with serotonergic agents
When sumatriptan is used together with ouabain, this leads to reduction in sumatriptan excretion
may enhance the serotonergic effect of serotonergic agents
may enhance the risk or severity of hypertension when combined
may have an increased hypertensive effect when combined with droxidopa
may increase the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists
Actions and spectrum:
Sumatriptan is an agonist of serotonin receptors 5-HT1B and 5-HT1D. By posing agonistic effects, it constricts the blood vessels in the brain and suppresses the release of pro-inflammatory neuropeptides. It also reduces the flow of blood in the carotid artery and increases the velocity of blood flow in the middle cerebral artery and internal carotid artery.
Adverse reactions
Frequency defined:
>10%
Dizziness
Reaction at the site of injection
Warm sensation
Paresthesia
1-10%
Abdominal stress
Burning sensation
Cold
Diaphoresis
Chest tightness
Dysphagia
Sore throat
Malaise
Frequency not defined
Dysuria
Cardiac arrhythmia
Nasal comfort
Palpitations
Eye irritation
Tingling
Weakness
Black box warning
Avoid using Sumatriptan within 24 hours after or before administration of another medicine for migraine
Do not use this medicine in case of coronary artery disease, heart disease, Wolff-Parkinson-White syndrome, hepatic impairment, heart attack or uncontrolled hypertension
Contraindications/Caution
Heart problems
Angina
Coronary artery disease
Wolff-Parkinson-White syndrome
Severe hepatic failure
Renal impairment
Epilepsy
Use of MAO inhibitors in the last two weeks
High blood pressure
Disorder of heart rhythm
Pregnancy & breastfeeding:
Pregnancy consideration:
USFDA pregnancy category–Â C
Breastfeeding warnings:
It should be used with caution in lactating mothers as the drug is known to be excreted into human milk.
Pregnancy category:
Pharmacology:
Sumatriptan belongs to the class of triptans. It is an agonist of the serotonin receptor.
Pharmacodynamics:
It constricts the cranial blood vessels and leads to the prevention of the release of vasoactive peptides. Depending on the route of administration, a dose of sumatriptan changes. Frequent use of this drug may cause headaches due to overuse of medications.
Pharmacokinetics:
Absorption: Cmax of 69.5ng/mL can be attained after administration of 6mg SC injection with 100% bioavailability.
Upon oral administration of 25mg of the drug, a Cmax of 16.5ng/mL can be obtained with a bioavailability of 14.3%.
A Cmax of 12.9ng/mL can be obtained following intranasal administration of 20mg of the drug.
Distribution: The volume of distribution is 50±8L for an SC dose of 6mg. 14-21% of the drug is known to be bound to proteins.
Metabolism: It is metabolized predominantly by monoamine oxidase A. The main inactive metabolites include indole acetic acid glucuronide and indole acetic acid.
Excretion: 22±4% of the drug is excreted in the urine in an unchanged form. 38±7% is eliminated through urine as indole acetic acid. Approximately 40% of the drug is eliminated through feces.
Half-life: SC-1.9hours
Oral- 1.7hours
Intranasal- 1.8hours
Rectal- 1.8hours
Administration:
This medicine should be administered immediately after the onset of headache symptoms.
Tablets should be administered orally.
Subcutaneous injections can be administered on their own upon proper training.
Patient information leaflet
Generic Name:Â sumatriptan
Why do we use sumatriptan?
Sumatriptan is used generally in treating migraine and cluster headaches including vomiting, nausea and sensitivity to sound or light. In combination with naproxen, it is indicated in the treatment of migraine without and with auras. It is available in various dosage forms.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
